TORONTO, Oct. 6, 2016 /PRNewswire/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) announced today that it has rescheduled its Annual and Special Meeting of Shareholders
to Thursday, December 15, 2016 at Mount Royal University, Roderick Mah Centre for Continuous
Learning (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at 9:00 am (MDT). A notice of meeting and management information circular containing the matters to be considered
at the meeting will be delivered to shareholders and filed on SEDAR at www.sedar.com on or before November 15, 2016.
Following the formal business of the meeting, Mr. Donald J. McCaffrey, President and Chief
Executive Officer, will deliver a corporate presentation which will be
webcast.
Webcast Details:
Date: Thursday, December 15, 2016
Time: Approximately 9:30 am MDT
Webcast Link: http://services.choruscall.ca/links/resverlogixagm20161215.html
The presentation will be available on the Company's website immediately prior to the start of the meeting. Click on this
LINK to go directly to the
appropriate page on the Company's website. An archived replay of the webcast will also be available on the Company's website by
clicking on this LINK.
Resverlogix has received an extension from the Toronto Stock Exchange to hold its Annual and Special Meeting of Shareholders
on December 15, 2016.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and
extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4.
This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits
for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease,
Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile.
Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial, BETonMACE, in
high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252,
Web: www.resverlogix.com
SOURCE Resverlogix Corp.